Cash Flow Statement

Amortizatization of Intangibles Asset Writedowns and Impairment Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Accured Expenses Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Free Cash Flow Gains from Investment Securities Net Cash Flow Net Income Non-cash Items Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Lyell Immunopharma (LYEL) Gains from Sales and Divestitures (2021)

Historic Gains from Sales and Divestitures for Lyell Immunopharma (LYEL) over the last 1 years, with Q3 2021 value amounting to $4.0 million.